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Abstract—Control of blood glucose is essential for diabetes
management. Current digital therapeutic approaches for subjects
with Type 1 diabetes mellitus (T1DM) such as the artificial
pancreas and insulin bolus calculators leverage machine learning
techniques for predicting subcutaneous glucose for improved
control. Deep learning has recently been applied in healthcare
and medical research to achieve state-of-the-art results in a range
of tasks including disease diagnosis, and patient state prediction
among others. In this work, we present a deep learning model
that is capable of forecasting glucose levels with leading accuracy
for simulated patient cases (RMSE = 9.38±0.71 [mg/dL] over
a 30-minute horizon, RMSE = 18.87±2.25 [mg/dL] over a 60-
minute horizon) and real patient cases (RMSE = 21.07±2.35
[mg/dL] for 30-minute, RMSE = 33.27±4.79% for 60-minute).
In addition, the model provides competitive performance in
providing effective prediction horizon (PHeff ) with minimal time
lag both in a simulated patient dataset (PHeff = 29.0±0.7 for
30-min and PHeff = 49.8±2.9 for 60-min) and in a real patient
dataset (PHeff = 19.3±3.1 for 30-min and PHeff = 29.3±9.4
for 60-min). This approach is evaluated on a dataset of 10
simulated cases generated from the UVa/Padova simulator and a
clinical dataset of 10 real cases each containing glucose readings,
insulin bolus, and meal (carbohydrate) data. Performance of the
recurrent convolutional neural network is benchmarked against
four algorithms. The proposed algorithm is implemented on an
Android mobile phone, with an execution time of 6ms on a phone
compared to an execution time of 780ms on a laptop.
Index Terms—Type 1 diabetes, continuous glucose monitor
(CGM), glucose prediction, deep learning, long short term
memory (LSTM).
I. INTRODUCTION
Diabetes is a chronic illness characterised by the absence of
glucose homeostasis. A healthy pancreas dynamically controls
the release of insulin and glucagon hormones through the α-
cells and β-cells respectively, in order to maintain euglycaemia
[1]. In Type 1 diabetes, an autoimmune disease, the β-
cells are compromised and therefore suffer from impaired
production of insulin. This leads to periods of hyperglycaemia
( persistent blood glucose (BG) concentration > 180mg/dL)
and hypoglycaemia (BG concentration < 70mg/dL) [2], [3].
Insulin therapy is needed to maintain BG levels in the advised
target range [4].
The standard approach to diabetes management requires
people actively taking BG measurements a handful of times
throughout the day with a finger prick test - self monitor-
ing of blood glucose. The recent development and uptake
of continuous glucose monitoring (CGM) devices allow for
improved sampling (5 minutes) of glucose measurements [5].
This approach has proven to be effective in controlling BG
and thus improving the outcome of subjects in clinical trials
[6]. Further improvement of glucose control can be realised
through prediction, which allows users to take actions ahead of
time in order to minimise the occurrence of adverse glycaemic
events. The challenges lie in multiple factors that influence
glucose variability, such as insulin variability, ingested meals,
stress and other physical activities [7]. In addition, individual
glycaemic responses are conditioned by high subject variabil-
ity [4], [8], leading to different responses between individuals
under the same conditions.
Machine learning (ML) allows intelligent systems to build
appropriate models by learning and extracting patterns in
data. The models discover mappings from the representation
of input data to the output. Performances of traditional ma-
chine learning algorithms such as logistic regression, k-nearest
neighbours [9], or support vector regression [10] heavily rely
on the representation of the data they are given. Typically, the
features - information the representation comprises - are en-
gineered with prior knowledge and statistical features (mean,
variance) [11], principal component analysis (PCA) [12] or
linear discriminant analysis [13]. Artificial neural networks
(ANN) are also investigated widely in diabetes management
[14]–[18]. One advantage of ANN is that normally no hand-
craft feature finding is required. However, ANN in the liter-
ature are mostly implemented fewer than 3 layers, hence its
learning capacity is limited due to the model complexity. Deep
learning, which incorporates multi-layer neural networks, has
lead to significant progresses in computer vision [19], diseases
diagnosis [20], and healthcare [21], [22]. Deep learning shows
superior performance to traditional ML techniques due to this
ability to automatically learn features with higher complexity
and representations [23]–[26]. As a result, it encodes features
that might not be previously known to researchers.
In this paper, we propose a deep learning algorithm for
glucose prediction using a multi-layer convolutional recurrent
neural network (CRNN) architecture. The model is primarily
trained on data comprising CGM, carbohydrate and insulin
data. After preprocessing, the time-aligned multi-dimensional
time series data of BG, carbohydrate and insulin (other factors
also can be considered) are fed to CRNN for training. The
architecture of the CRNN is composed of three parts: a multi-
layer convolutional neural network that extracts the data fea-
tures using convolution and pooling, followed by a recurrent
neural network (RNN) layer with long short term memory
(LSTM) cells and fully-connected layers. The model is trained
end-to-end. The convolutional layer comprises a 1D Gaussian
kernel filter to perform the temporal convolution, and pooling
layers are used for reducing the feature set. A variant of LSTM
2model is leveraged since LSTM shows good performances in
predicting time series with long time dependencies [27]. The
final output is a regression output by fully connected layers.
The CRNN model is realized using the open-source software
library Tensorflow [28], and it can be easily implemented
to portable devices with its simplified version Tensorflow
Lite. The performance of the proposed method is evaluated
on datasets of simulated cases as well as clinical cases of
T1DM subjects, and compared against benchmark algorithms
including support vector regression (SVR) [10], the latent
variable model (LVX) [29], the autoregressive model (ARX)
[30], and neural network for predicting glucose algorithm
(NNPG) [14]. The results show the competitive performance
of the method.
As far as we know, the proposed method is a pioneering
work in glucose forecast implementing deep neural networks
that incorporates the merits of both CNN and RNN, and
we modify them to suit the task of glucose prediction. It
achieves competitive performances in terms of forecasting
accuracy comparing to benchmark methods, with superior
performances in terms of RMSE. It applies multi-layer NN in
smart phones with applications in diabetes management. The
paper is organized as follows. Section II briefly introduces the
properties of the glucose data. Section III addresses the method
and architecture of the proposed convolutional recurrent neural
network. The performance of the proposed method is evaluated
and discussed in Section IV. Section V discusses important
details of the method. Finally Section VI summaries the paper.
II. DATA ACQUISITION AND SETTING
A. Data Acquisition
The data used in this paper include two datasets, in-silico
data and clinical data. In-silico data consisting of 10 adult
T1DM subjects was generated using the UVA/Padova T1D,
which is a simulator for glucose level simulation approved
by the Food and Drug Administration (FDA) [31]. In this
work, we used a modified version of the simulator which
includes such variability. In particular, the variability on meal
composition, insulin absorption, carbohydrate estimation and
absorption, and insulin variability were included. In addition,
a simple model of physical exercise was also used. Details
about how the simulator was modified can be found in [32].
Clinical data was obtained from a clinical study at Imperial
College Healthcare NHS Trust St. Marys Hospital, London
(UK) consisting of multiple phases evaluating the benefits of
an advanced insulin bolus calculator for T1D subjects [33].
The dataset in consideration was collected from a 6-month
period involving 10 adult subjects with T1D. The information
included in the dataset comprises glucose, meal, insulin, and
associated time stamps. In building the dataset, we mainly
consider CGM and self-reported data such as insulin boluses,
meals, and exercise similar to the in-silico dataset. Before
that, we exclude participants whose data exhibited large gaps
(corresponding to weeks of missing data), insufficient reports
of exercise over the 6-month period, and extensive errors in
sensor readings.
The CRNN model can be applied to datasets where other
inputs are available, such as self-reports of exercise, stress
and alcohol consumption. We believe that these information
are useful and will increase the forecast accuracy in some
cases. But in this section we only consider CGM data recorded
every 5 minutes, meal data indicating meal time and amount of
carbohydrates, as well as insulin data with each bolus quantity
and the associated time as input in the model.
B. Data Setting
The in silico data considered in this section is generated via
UVA/Padova T1D. This simulator serves as robust and vali-
dated framework for generating simulated cases. The cohort of
T1D cases generated can be configured with varying meal and
insulin information such that each case sufficiently differs. We
generate a dataset of 10 unique adult cases and each has 360
days of data for each case. There are 3 meals per day. Insulin
entries vary in each day, from 1 to 5. The insulin entry can
be with a meal (meal and insulin at almost the same time), or
without a meal (correction bolus). A simple exercise model is
considered at certain points, which occur occasionally at any
time except for nights. The training data accounts for 50% of
the dataset, and the testing set is the rest of data.
The clinical data was collected from T1DM subjects in a 6
month clinical trial. The CGM data was measured using Dex-
com G4 Platinum CGM sensors , with measurements received
every 5 minutes. The CGM sensors were inserted from the first
day of the study, and calibrated according to the manufacturer
instructions. Other information available in the dataset such
as meal, insulin, exercises was logged by the diabetic subjects
themselves. Though the selected data has good quality, many
periods of missing data, bad points or unexpected fluctuations
exist. Similar to the in silico experiment, each subject’s clinical
data is halved for training and testing data.
III. METHODS
After introducing the data acquisition and setting, the
method is explained explicitly. The approach consists of sev-
eral components: preprocessing, feature extraction using CNN,
time series prediction using LSTM and a signal converter. The
architecture of the proposed CRNN is shown in Fig. 1. In the
diagram, the input of the algorithm is time series of glycaemic
data from CGM, carbohydrate and insulin information (time
and amount); other related information are optional (exercises,
alcohol, stress, etc.). The output of preprocessing is cleaned as
time-aligned glycaemic, carbohydrate and insulin data, which
are then fed to the CNN. The output of CNN serves as
the input of RNN, which is a multi-dimensional time series
data, representing the concatenation of features of the original
signals. The output of the RNN is the predictive BG level 30-
min (or 60-min) later, while hidden states are inherited and
updated continuously internally inside of the RNN component.
The model is trained end-to-end. We evaluate the models with
30 and 60-min prediction horizon (PH) because it is widely
used in glucose prediction software, and is easier to compare
results with other works [10], [14], [16], [29], [34], [35]. We
proceed with an explanation data pipeline and components of
the model architecture.
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Fig. 1. The architecture of the proposed convolutional recurrent neural network for BG prediction. The data at the left is the concatenated time series data
including glucose level, carbohydrate, insulin and other factors. After outlier filtering, the multi-dimensional data can be sent to the multi-layer convolutional
component. Then the resultant time series is sent to the modified recurrent neural network component presented in a red frame, which includes LSTM cells
and dense fully connected layer. Finally, the resultant is converted back from “change of the glucose value” to “absolute glucose value”. The output is the
future glucose values of PH (eg. PH = 30 mins).
A. Outlier Detection and Filtering
The main purpose of the preprocessing component is to
clean the data, filter the unusual points and make it suit-
able as the input to the neural network. Besides the normal
steps including time stamp alignment and normalization, the
most important operation to improve the data quality is the
outlier detection, interpolation/extrapolation and filtering, in
particular for clinical data. Because in clinical data, there
are many missing or outlier data points due to errors in
calibration, measurements, and/or mistakes in data collection
and transmission. Here, several methods can be used to handle
these scenarios [36]. They include dimension reduction model
to project data into lower dimensions [37], proximity-based
model to determine the data by cluster or density [38], and
probabilistic stochastic filters [39] to rule out outliers.
For some cases when the data fluctuates with high fre-
quency, 1D Gaussian kernel filter can be implemented on the
glucose time series. A smoothed continuous time series of
glycaemic data can be obtained, along with the time-aligned
carbohydrate and insulin information. In this paper, for in
silico data we do not use filters because the dataset is already
clean. For clinical data used in this paper, we use the Gaussian
filter. The 3-dimensional time series that covers the last 2 hours
before the current time is sent to the neural network as input.
A sliding window of size 24 is determined to train the model.
This is because during the experiments we found that 24 is an
optimal setting considering the tradeoff between the prediction
accuracy and the computation complexity. In [14] the NNPG
algorithm uses a similar window size of 20.
B. A Multi-layer Convolutional Network
The filtered time series signal goes through the multi-
layer convolutions, which transform the input data into a
set of feature vectors. The convolution operation follows the
temporal convolution definition in which
z[m] =
l∑
i=−l
x[i] · δ[m− i], (1)
where x represents the input signal, δ denotes the kernel, z
is the result of the convolution, and m is the result’s index.
Specifically in the first layer, x’ length is the sliding window
size of 24, kernel δ has a size of 8. The dimension of data
in each layer is detailed in Appendix. The input signal can
be fed using a sliding window setting. The windows can
be overlapped or non-overlapped, determined by the allowed
CNN size and computations. The CNN automatically learns
the associated weights and recognises particular patterns and
features in the input signal that can best represent the data for
future time steps. It is illustrated in Fig. 2.
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Fig. 2. An illustration of the proposed CNN architecture. The multi-
dimensional aligned time series data are concatenated, and then sent to a
multi-layer CNN composed of convolutional layers and pooling layers. Finally,
after going through a fully connected layer, the final output is the summation
of the model output and a copy of the original CGM time series.
The proposed CNN consists of 3 convolutional layers,
with max pooling applied to down-sample the feature map
obtained from the previous convolutional layer. It is common
to periodically insert a pooling layer in-between successive
convolutional layers to progressively reduce the size of the
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Fig. 3. An illustration of the proposed modified recurrent neural network in the inference. It origins from the conventional LSTM cell, including an input
gate, an output gate and a forget gate. The difference lies in the output part, which indicates in red colour in the figure. The output of ht is still the internal
parameter which is transmitted to the next cell. However, the output value signal is yt instead of ht. It is because in the training process, the target of RNN
is the change of the glucose value between current time and 30 mins later. Thus the predictive glucose level after 30 mins should be the inference value plus
the current glucose value.
representation, as well as the computation. It also guards
against the problem of overfitting. For instance, if the accepted
size is L1×D1, and the down-sampled parameters are spatial
extent F and stride S, and it results in a max-pooling vector
Y of size L2×D2 where
L2 = (L1− F )/S + 1; D2 = D1; Yi = max(y∗i ) (2)
where y∗i is the vectors after being down-sampled, Yi is the
feature map and max() is the operator that computes the maxi-
mum value. During the training process, the CNN is trained by
back-propagation and the stochastic gradient descent method.
The initial weights of the network are set randomly, and the
mean-absolute-error is set as the cost function to be minimised
in the training. Partial derivatives of the error in terms of the
weights wi and bias bi are computed, and the associated wi
and bi are updated accordingly. The last convolutional layer
feeds directly into the recurrent layer that makes up the next
component in the architecture.
C. A Modified Recurrent Layer
An LSTM network comprised of 64 LSTM cells is adopted
as recurrent layers [40]. Each LSTM cell consists of an input
gate, an output gate and a forget gate. Each of the three gates
can be thought of as a neuron, and each gate achieves a
particular function in the cell. The LSTM network is good at
building predictive models for time series and sequential data
[41]. These cells retain previous data patterns over arbitrary
time intervals, thus the internal “memory” can predict the
future output according to the previous states. Its memory can
be updated simultaneously when new data are fed to the model.
The output of the CNN, a multi-dimensional time series, is
connected to the LSTM network. We generated an RNN with 1
hidden layer, consisting of a wide LSTM layer consisting of 64
cells. A dropout applied after the LSTM layer. Dropout refers
to ignoring neurons randomly during the training phase. It has
been verified that in many cases that dropout can effectively
avoid overfitting problems and improve the generalisation [42].
The main difference between a normal LSTM and the
proposed LSTM is that the proposed model has a transform
and a recovery step. They modify BG values before and after
the conventional LSTM. In training phase, instead of BG
values directly, we use the changes of BG between the current
BG x(t) and the future BG x(t + 6) as target labels. It is
called the transform step. The input sliding window matrices
are multi-dimensional time series (including BG values, meal,
insulin). After the model has been trained, the inference output
is the change of BG 4x(t) between x(t) and x(t+ 6). Thus
the prediction of BG at time t + 6 can be calculated as
x(t+ 6) = x(t) +4x(t). This is called the recovery step.
Specifically, a modified LSTM estimates the conditional
probability p(y1, · · · , yT ′ |x1, · · · , xT ) given a sequence of
data, where x1, · · · , xT denotes the input sequence and
y1, · · · , yT ′ is the corresponding output sequence, with size T
and T ′ respectively. If xt, ht, ct are used to denote the input
vector, output vector and memory cell vector respectively;
W,U, and b are the parameter matrices/vectors that can be
learned in the network. ft, it, and ot denote the forget gate,
input gate, and output gate vectors. Then mathematical form
of the update process can be explicitly written as
ft = σg(Wfxt + Ufht−1 + bf ) it = σg(Wixt + Uiht−1 + bi)
ot = σg(Woxt + Uoht−1 + bo) gt = σt(Wgxt + Ught−1 + bg)
ct = ft ◦ ct−1 + it ◦ σt(gt) ht = ot ◦ σt(ct),
yt = ot ◦ σt(ct) + xt,
(3)
where σg, σt, ◦ is the sigmoid function, hyperbolic tangent and
entrywise product, respectively. In (3), the 1st to 5th equations
are the same to the equations of normal LSTM. However
the last 2 equations of ht and yt are modified accordingly.
It has been shown in Fig. 3, where the difference between the
proposed modified LSTM and the normal LSTM is indicated
in red. The output of the LSTM cell is not ht, but yt in
inference. The ht is used as an internal hidden state that goes
to the next time step. The output yt is calculated from ht plus
the original input xt. That is because the output (and targets)
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Fig. 4. A flow diagram explains the procedure to implement deep learning
models as Tensorflow Lite files to portable devices. In the figure, yellow square
frames denote the models or files obtained after each operation, and yellow
elliptic frames denote the associated operations applied. After TF Lite model
files are created, they can be deployed in Android or iOS app with slightly
different settings as shown in the cylinders.
of the neural network is the change of the BG level. The value
of the predictive glucose level needs to be recovered from the
glucose change by adding the baseline glucose value.
Finally, the last layer of RNN feeds a multi-layer fully
connected network, which consists of 2 hidden layers (256
neurons and 32 neurons) and an output layer (a single neuron)
with the glucose change as output. The fully connected layer
produces the output with an activation function
Zi = act(
N∑
i=1
Yiwi + bi), (4)
where Zi is the multi-dimensional output, act() is an activation
function, wi and bi are weights of the fully connected network.
Particularly, act() can be chosen from a set of activation func-
tions such as sigmoid function act(a) = 1/(1+e−a), rectifier
act(a) = log (1 + exp(a)) or simple linearly act(a) = a. In
this paper we choose the linear function act(a) = a as the
activation function for its simplicity. In the training, a gradient
descent optimisation is used. The mean absolute error between
the target and the predictive value is being minimised. The
optimiser we use is RMSprop, because it is a good choice
for recurrent neural networks. It usually maintains a moving
(discounted) average of the square of gradients [43], and
divides gradient by the root of this average.
D. Software and Hardware
After the model has successfully undergone training and
validation, we implement our algorithm on mobile phones
through Tensorflow Lite due to its efficiency running on
portable devices. The model is converted to a Lite model
file and installed on an Android or iOS system. It needs
the associated application programming interface (API) and
interpreter to carry out the inference. Fig. 4 shows how the
Tensorflow Lite model file [28] is wrapped and loaded in a
mobile-friendly format.
CGM sensors were used to collect data. We utilize com-
puters equipped with graphics processing unit (GPU) to carry
out the training and inference processes. In practice an Intel
i7-7700K CPU with 4.20 GHz, 32.0 GB memory with GPU
NVIDIA GeForce GTX 1080 Ti were used in the experiments.
The program was written in Python 3.6, using CUDA 9.0 to
perform the parallel computing. Tensorflow architecture was
implemented, because its compatibility and merits for large-
scale distributed training and inference.
IV. RESULTS
In this section we test the proposed CRNN algorithm for
glucose level forecasting using a in silico dataset and a clinical
dataset. The performance of the proposed algorithm is con-
trasted with that of four baseline methods: NNPG, SVR, LVX
and ARX (3rd order). The results are compared with the same
input data after the same pre-processing. The performance of
the methods are compared based on the accuracy over 30-
and 60-minute prediction horizon. In addition, we evaluate the
time lag of the prediction. Different algorithms were tested on
the in silico data generated in a way described previously. The
parameters involved in these algorithms are tuned carefully for
optimal result. In SVR, the SVR function in Python is applied
with the optimal parameters (C = 1e2, γ = 0.01, cachesize =
1000). The LVX method is applied based on the MATLAB
code provided in [29], the optimal predictor length and the
number of LVs are Jx = 4 and NLV = 4 respectively. This
represents 20-minute historical data of glucose measurement,
insulin and meal information being used for prediction. The
3rd order ARX model is optimized by MATLAB function
arx() for every specific subject.
A. Criteria for Assessment
Several criteria are used to test the performance of the
proposed algorithm. The root-mean-square error (RMSE) and
mean absolute relative difference (MARD) between the pre-
dicted and reference glucose readings serve as the primary
indicators to evaluate the accuracy.
RMSE =
√√√√ 1
N
N∑
k=1
(y(k)− yˆ(k|k − PH))2, (5)
where yˆ(k|k − PH) denotes the prediction results provided
the historical data and y denotes the reference glucose mea-
surement, and N refers to the data size.
MARD =
1
N
N∑
k=1
|yˆk(k|k − PH)− y(k)|
y(k)
. (6)
The RMSE and MARD provide an overall indication of the
predictive performance. As mentioned earlier, the benefit of
glucose prediction is avoiding adverse glycaemic events. In the
clinical context, these metrics are limited in the insight they
provide. Additional metrics are needed to assess the proposed
algorithm in the following perspective:
• Capability of the forecasting algorithm in differen-
tiating between adverse glycaemic events and non-
adverse glycaemic events.
• Time delay in the predicted glucose readings and ref-
erence values to evaluate the response time provided
to deal with the potential adverse glycaemic event.
6The Matthews Correlation Coefficient (MCC) is used to
evaluate the performance of the algorithms for detecting either
adverse glycaemic event (hypoglycaemia or hyperglycaemia).
MCC=
(TP × TN)−(FP × FN)√
(TP+FP )(TP+FN)(TN+FP )(TN+FN)
,
(7)
where TP, FP, FN, TN stand for true positive, false positive,
false negative, and true negative respectively. Here, positive
indicates a hypoglycaemia (< 70 mg/dL)/hyperglycaemia (>
180 mg/dL) event in the next or previous 30 or 60 minutes, and
true means that the classification is correct. We consider a true
adverse event to have occurred when either scenario persists
in the CGM data for at least 20 minutes [44]. In addition, we
consider an event a True Positive when the predicted event is at
most 10 minutes (PH+2 timesteps ahead) leading or within 25
minutes of the prediction horizon lapsing (1 timestep for PH =
30 min, and 7 timesteps for PH = 60 min) the reference event.
A standard confusion matrix typically includes the Accuracy
as opposed to Matthews Correlation Coefficient (MCC). This
modification addresses the imbalance in classes inherent in this
situation - non-adverse events far outweigh adverse events.
The effective prediction horizon is defined as the prediction
horizon, taking into account delays due to the responsiveness
of the algorithm for a predicted value relative to its reference
value. Cross correlation of the predicted and actual readings is
employed in performing a time delay analysis of the proposed
algorithm to determine the effective prediction horizon.
PHeff = PH − τdelay
= PH − argmax
τ
(yˆk(k|k − PH) ? y(k)). (8)
A singular quantitative metric is not sufficient in evaluating
performance of the proposed algorithm. Consequently, the
set of metrics collectively give a comprehensive description
of the quality of the prediction algorithm performance. p-
values are calculated for other algorithms comparing to the
proposed algorithm in terms of smaller RMSE, MARD or
longer PHeff . A Shapiro-Wilk Test is used to ascertain the
normality of the results before performing a paired t-test to
derive the p-values. Across all results, the tests show the
null hypothesis (samples drawn from a Gaussian distribution)
cannot be rejected.
B. In Silico Data
The results of RMSE, MARD and forecasting of adverse
glyvaemic events are summarized in the Table I. In the Table
we compare the predictive error of the algorithms to measure
the accuracy of the algorithms. The CRNN algorithm exhibits
the best overall RMSE and MARD for the 10 simulated cases
at short(30) and long term(60) predictions. The results in Table
I are statistically significant relative to each algorithm. This
observation is also evident in both the hyperglycaemia and hy-
poglycaemia region. In the hyperglycaemia region the CRNN
shows a statistically significant improvement in the glucose
prediction over most other algorithms, with the exception of
LVX. CRNN reports a statistically significant improvement in
TABLE I
RMSE AND MARD COMPARISON OF DIFFERENT PREDICTION METHODS
FOR 10 VIRTUAL ADULT DIABETIC SUBJECTS
PH Metric CRNN NNPG SVR LVX ARX
30
Overall
RMSE 9.38 12.91‡ 12.48‡ 11.32† 13.27‡
(mg/dL) ±0.71 ±1.19 ±1.94 ±1.34 ±1.19
MARD 5.50 7.05‡ 6.40 6.59‡ 7.46‡
(%) ±0.62 ±0.94 ±1.36 ±0.80 ±1.02
Hyperglycaemia
MCC 0.84 0.83 0.84 0.83 0.81
±0.05 ±0.04 ±0.04 ±0.04 ±0.05
Hypoglycaemia
MCC 0.79 0.64 0.79 0.83 0.78
±0.15 ±0.20 ±0.10 ±0.06 ±0.10
Effective Prediction Horizon
Time 29.0 20.8‡ 23.3‡ 27.5† 20.5‡
(min) ±0.7 ±1.8 ±1.6 ±1.3 ±1.7
60
Overall
RMSE 18.87 24.24‡ 23.46‡ 22.42† 25.73‡
(mg/dL) ±2.25 ±3.01 ±3.33 ±2.74 ±3.24
MARD 9.16 13.70‡ 10.83 12.20‡ 13.75‡
(%) ±1.16 ±1.88 ±1.48 ±1.82 ±2.45
Hyperglycaemia
MCC 0.82 0.79 0.78 0.86 0.64
±0.05 ±0.06 ±0.07 ±0.04 ±0.05
Hypoglycaemia
MCC 0.80 0.38 0.79 0.80 0.72
±0.14 ±0.39 ±0.10 ±0.07 ±0.12
Effective Prediction Horizon
Time 49.8 31.0‡ 32.6‡ 44.2‡ 19.8‡
(min) ±2.9 ±4.7 ±4.1 ±2.7 ±2.7
*
p-value ≤ 0.05 †p-value ≤ 0.01 ‡p-value ≤ 0.005
effective prediction time (+1.5min for 30-min and +5.6min for
60-min) over LVX, and it is better than the rest thus giving
the user more time to take action. On the whole CRNN can
be evaluated as the best algorithm. The CRNN model also
reports relatively low standard deviations from which we infer
a benefit in building individualized models.
An illustration of a comparison of various algorithms for 30-
minute shown in Fig. 5 for a virtual adult 4. As seen in the Fig.
5, the CRNN exhibits the best responsiveness as the predictive
curve responds rapidly towards the sharp glycaemic uptrend.
The algorithm learns representations that appropriately ac-
count for both sharp slopes and gradual increments in the
glycaemic curve. Consequently, at a glycaemic peak, CRNN
yields a predictive curve with even higher slope to compensate
the time lag aiming at reducing the gap between the prediction
and real measurements. This feature helps CRNN to decrease
the RMSE and MARD as well as maximising the effective
prediction horizon.
C. Clinical Data
As mentioned in the previous section, the data obtained in
the clinical trial exhibits missing data, and erroneous data. This
results in non-physiological discontinuities that would affect
the training process. To mitigate these occurrences, the data is
processed with interpolations/extrapolations for gaps in data.
The interpolation/extrapolations points are not included in the
evaluation of the performance of the methods.
712:00 06:00 12:00 06:00 12:00 06:00
Time Dec 22, 2017-Dec 23, 2017   
60
80
100
120
140
160
180
200
220
240
Gl
uc
os
e(m
g/d
l)
Comparisons of Glucose Predictive Curves.
Real Measurements
ARX
SVR
LVX
CRNN
Fig. 5. One-day period prediction results for virtual adult 4. The solid black line, dotted green line, solid magenta line, dashed blue line, dash-dotted red line
indicate the simulated glucose measurements, the prediction results of the 3rd order ARX method, the prediction results of the SVR method, the prediction
results of the LVX algorithm, the prediction results of the CRNN method, respectively.
TABLE II
RMSE AND MARD COMPARISON OF DIFFERENT PREDICTION METHODS
FOR 10 REAL ADULT DIABETIC SUBJECTS
PH Metric CRNN NNPG SVR LVX ARX
30
Overall
RMSE 21.07 23.14 22.00 21.51 21.56
(mg/dL) ±2.35 ±2.99 ±2.83 ±2.44 ±2.53
MARD 11.61 13.42 13.54 10.93 11.00
(%) ±2.18 ±2.35 ±2.88 ±1.87 ±1.81
Hyperglycaemia
MCC 0.79 0.75 0.79 0.79 0.77
±0.04 ±0.04 ±0.05 ±0.04 ±0.04
Hypoglycaemia
MCC 0.51 0.12‡ 0.11‡ 0.55 0.53
±0.2 ±0.12 ±0.08 ±0.17 ±0.15
Effective Prediction Horizon
Time 19.3 12.8† 18.6 14.5 12.0*
(min) ±3.1 ±2.9 ±2.8 ±3.4 ±3.0
60
Overall
RMSE 33.27 36.05‡ 34.35† 37.46‡ 36.97‡
(mg/dL) ±4.79 ±4.85 ±4.55 ±5.04 ±4.75
MARD 19.01 21.98‡ 20.65 19.69‡ 19.65‡
(%) ±4.46 ±4.87 ±3.92 ±3.70 ±3.55
Hyperglycaemia
MCC 0.72 0.66* 0.74 0.76 0.71
±0.05 ±0.09 ±0.07 ±0.05 ±0.05
Hypoglycaemia
MCC 0.40 0.01‡ 0.06‡ 0.56* 0.51
±0.13 ± 0.00 ±0.08 ±0.14 ±0.15
Effective Prediction Horizon
Time 29.3 18.3‡ 28.4 19.9* 13.6‡
(min) ±9.4 ±4.9 ±5.2 ±5.1 ±3.7
*
p-value ≤ 0.05 †p-value ≤ 0.01 ‡p-value ≤ 0.005
Table II shows the RMSE and MARD of the performance
of the algorithms for the 10 cases of real data. Contrary
to the relative performance of the methods in the in-silico
dataset, the evaluation of the methods is mixed. The CRNN
maintains the best results for RMSE and MARD over a
30 minute prediction horizon baseline methods. However,
the ARX and LVX models show improved performance in
terms of MARD relative to the CRNN. In addition, the LVX
shows marginally better performance over CRNN in predicting
adverse glycaemic events. The time delay in predicting these
results shows that CRNN exhibits the best performance with
the smallest lag.
Over a long-term prediction horizon, the CRNN provides
the best performance for prediction of glucose level and
with the least lag of the evaluated methods. SVR is able to
perform close to the CRNN in terms of effective prediction
horizon. However, the better prediction of hyperglycaemic
events is contrasted with very poor prediction of hypogly-
caemia. The results for hypoglycaemia prediction, equivalent
to random guessing, suggest that 60 minutes represents the
limit of meaningful hypoglycaemia prediction for SVR and
NNPG given these inputs. Further improvement may require
the inclusion of engineered features. Although LVX exhibits
superior performance in predicting adverse glycaemic events,
it should be noted that the user would have considerably less
time (-9 mins) to take action. As seen in Fig. 6, the CRNN
and LVX both achieve good predictive curves compared to
the ground truth measurements. Specifically, at the inflection
periods during peaks and troughs, the LVX tends to have
higher and lower predictions, respectively. The CRNN follows
the trend at both local and global peak points closely, which
increases its overall accuracy.
To understand the effect of each network component, we
generate networks with different components and evaluate
their performances. The results are shown in Table III. It
shows that full CRNN achieves the best performance, and both
CNN and LSTM component contribute to the final result. In
addition, we investigate the influence of different lengths of
8Fig. 6. One-day period prediction results for clinical adult 17. The solid black line, dotted green line, solid magenta line, dashed blue line, dash-dotted red
line indicate the real glucose measurements, the prediction results of ARX, SVR, LVX, and the CRNN algorithm, respectively.
training set. The results are shown in Table IV. Using 1 month
training data, the RMSE of CRNN can achieve 22.28± 2.67
(30) and 35.56 ± 4.55 (60). This can be slightly improved
if longer training data are exploited. It shows that collecting
more training data can increase the predictive accuracy.
TABLE III
AN ABLATION STUDY SHOWING THE EFFECT OF EACH STAGE ON CRNN
PERFORMANCE
Model RMSE30 min 60 min
CRNN 21.07± 2.35 33.27± 4.79
CRNN w/o CNN 22.16± 4.39 36.28± 7.14
CRNN w/o LSTM 21.50± 2.62 36.01± 6.41
TABLE IV
A TABLE SHOWING THE PERFORMANCE WITH DIFFERENT PERIODS OF
TRAINING DATA
Training
Data
RMSE
30 min 60 min
3 months 21.07± 2.35 33.27± 4.79
2 months 22.07± 2.84 35.12± 4.69
1 month 22.28± 2.67 35.56± 4.55
V. DISCUSSION
A. Performance in Simulated and Clinical Data
In this paper, both in silico and clinical dataset are verified.
The in silico dataset is for test. The clinical dataset, as
real data collected from clinical trials, are more practical
and significant if people want to compare the performances
of different methods. In the previous section we noted a
discrepancy in the performance of the proposed algorithm and
baseline algorithms in simulated cases and the real patient
cases. Previous tests have also indicated that the performance
in real subjects is much less satisfactory comparing to virtual
subjects. In our opinion, the drop in performance can be
primarily attributed to the increased complexity of real data
generated from a patient relative to the simulated data gener-
ated from a physiological model. In addition the gaps in data
and method of interpolation/extrapolation may contribute to
the further reduction in performance. Relative to the baseline
algorithms, the CRNN is better at capturing the features since
deep learning affords a better capacity at learning optimal
representations of features. This would explain the relatively
lower variance in metrics for the performance of the CRNN
in different cases relative to baseline models.
B. Results Comparisons
We achieved a mean RMSE = 9.38mg/dL in silico using the
proposed method, and it is the best amongst other algorithms,
including SVR, LVX and 3rd order ARX. In addition, we
want to compare our algorithm with other approaches in the
literature. Using the dataset generated from the simulator, our
algorithm is better than the results of RMSE = 18.78mg/dL
[34] and RMSE = 13.65mg/dL in [35]. For several other
works, it is difficult to evaluate the RMSE through direct
comparison due to the unavailability of the original codes,
parameters of the models, and the benchmark datasets. How-
ever, we may compare the results with widely used methods as
benchmarks, such as SVR or NNPG. For instance, for PH = 30
min as shown in Table 3 [16], the algorithm is 0.1 mg/dL better
than the result of SVR in terms of RMSE on the real dataset;
our algorithm is 0.9 mg/dL better than the SVR in terms of
RMSE on the real dataset. In [15], for PH = 30 min their
RMSEs are 1.3 better than NNPG for the simulated data and
0.2 mg/dL better than NNPG for the real datasets. Our RMSEs
are 3.5 mg/dL better than NNPG for the simulated data and
2.1 mg/dL better for the real datasets. As far as we know,
9the proposed algorithm achieves a performance state-of-the-art
accuracy with regard to RMSE. To build a fair comparison,
we provide all benchmark models the same input, including
CGM data, meal and insulin. For the conventional NNPG, it
only uses CGM measurements. Thus in the comparison we
incorporates meal and insulin in the input as well to generate
an enhanced NNPG.
C. Application on resource-constrained mobile platforms
CRNN is a personalised algorithm for different diabetic sub-
jects. Firstly, it is data driven and personalised. Secondly, the
model can be continuously updated as more data is available.
In details, the model is saved as a trained neural network.
We use the sequential model with Tensorflow backend to
train the neural network, and the result can be saved as
a small file. This file can be compiled as a “.tflite” or a
“.pb” file for the app on mobiles, by using a Tensorflow
Lite converter. The model file can be updated continuously at
the cloud. The app may demonstrate the predictive glycaemic
curve on screen. A demonstration on the Android system is
shown in Fig. 7 In addition, we also found that the execution
time of the model is 6ms on a Android phone (LG Nexus5
with Processor: 2.26GHz quad-core, RAM:2GB) and 780ms
on a laptop (MacPro with Processor: 3.1GHz Intel Core i5,
RAM:8GB). The reasons might be in the quantisation of
weights and biases (e.g. 8 bit integer vs. 32 bit floating point),
thus leading to a faster computation.
Fig. 7. An illustration of the glucose level shown in an app interface on an
Android system, where the red curve is the historic blood glucose, black dash
line is the current time, and the red dot curve is the prediction provided by
the model.
D. Limitations
Though CRNN has achieved very good accuracy in pre-
diction, some challenges remain. Notably the performance
in predicting hypoglycaemia degrades much faster than the
performance in predicting hyperglycaemia as the prediction
horizon increases. This can relate to the intervention with
unaccounted fast acting (< 15 mins) carbohydrates to prevent
onset of hypoglycaemia or aerobic exercise which can acceler-
ate onset of hypoglycaemia. Over farther prediction horizons,
future events may need to be accounted for to improve
the performance. In addition, meal/bolus rules supported by
physiological models might be added to the model. Based on
the CRNN approach proposed in this paper, it is possible to
develop a hybrid method, which may have the advantages of
both conventional and deep learning algorithms.
VI. CONCLUSION
In this paper a convolutional recurrent neural network
was proposed as an effective method for BG prediction.
The architecture includes a multi-layer CNN followed by a
modified RNN, where the CNN could capture the features or
patterns of the multi-dimensional time series. The modified
RNN is capable of analyzing the previous sequential data and
providing the predictive BG. The method trains models for
each diabetic subject using their own data. After obtaining
the trained neural network, it could be applied locally or
on portable devices. The proposed CRNN method showed
superior performance in forecasting BG levels (RMSE and
MARD) in the in silico and clinical experiments.
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VIII. APPENDIX
TABLE V
A TABLE DETAILING THE SIZE AND DIMENSIONS OF LAYERS IN CRNN
Layer Description Output DImensions No. of
(layer) Parameters
Convolutional Layers (Batch×Steps×Channels)
(1) 1×4 conv 128(1)× 24× 8 104
max pooling, size 2 128(1)× 12× 8 −
(2) 1×4 conv 128(1)× 12× 16 528
max pooling, size 2 128(1)× 6× 16 −
(3) 1×4 conv 128(1)× 6× 32 2080
max pooling 128(1)× 3× 32 −
Recurrent Layer (Batch×Cells)
(4) lstm 128(1)× 64 24832
Dense Layers (Batch×Units)
(5) dense 128(1)× 256 16640
(6) dense 128(1)× 32 8224
(7) dense 128(1)× 1 33
REFERENCES
[1] N. D. D. Group, “Classification and diagnosis of diabetes mellitus and
other categories of glucose intolerance,” Diabetes, vol. 28, no. 12, pp.
1039–1057, 1979.
[2] A. Facchinetti, S. Favero, G. Sparacino, and C. Cobelli, “An online
failure detection method of the glucose sensor-insulin pump system: Im-
proved overnight safety of type-1 diabetic subjects,” IEEE Transactions
on Biomedical Engineering, vol. 60, no. 2, pp. 406–416, Feb. 2013.
[3] S. Zavitsanou, A. Mantalaris, M. C. Georgiadis, and E. N. Pistikopoulos,
“In silico closed-loop control validation studies for optimal insulin deliv-
ery in type 1 diabetes,” IEEE Transactions on Biomedical Engineering,
vol. 62, no. 10, pp. 2369–2378, Oct. 2015.
[4] M. Vettoretti, A. Facchinetti, G. Sparacino, and C. Cobelli, “Type
1 diabetes patient decision simulator for in silico testing safety and
effectiveness of insulin treatments,” IEEE Transactions on Biomedical
Engineering, pp. 1–1, 2018.
10
[5] M. M. Ahmadi and G. A. Jullien, “A wireless-implantable microsys-
tem for continuous blood glucose monitoring,” IEEE Transactions on
Biomedical Circuits and Systems, vol. 3, no. 3, pp. 169–180, Jun. 2009.
[6] A. Facchinetti, “Continuous glucose monitoring sensors: Past, present
and future algorithmic challenges,” Sensors, vol. 16, no. 12, 2016.
[7] S. Oviedo, J. Veh, R. Calm, and J. Armengol, “A review of personalized
blood glucose prediction strategies for t1dm patients,” International
Journal for Numerical Methods in Biomedical Engineering, vol. 33,
no. 6, p. 2833, 2017.
[8] P. Pesl, P. Herrero, M. Reddy, M. Xenou, N. Oliver, D. Johnston,
C. Toumazou, and P. Georgiou, “An advanced bolus calculator for type
1 diabetes: System architecture and usability results,” IEEE Journal of
Biomedical and Health Informatics, vol. 20, no. 1, pp. 11–17, Jan 2016.
[9] A. G. Karegowda, M. Jayaram, and A. Manjunath, “Cascading k-
means clustering and k-nearest neighbor classifier for categorization of
diabetic patients,” International Journal of Engineering and Advanced
Technology, vol. 1, no. 3, pp. 2249 – 8958, 2012.
[10] E. I. Georga, V. C. Protopappas, D. Ardig, M. Marina, I. Zavaroni,
D. Polyzos, and D. I. Fotiadis, “Multivariate prediction of subcutaneous
glucose concentration in type 1 diabetes patients based on support
vector regression,” IEEE Journal of Biomedical and Health Informatics,
vol. 17, no. 1, pp. 71–81, Jan 2013.
[11] K. Yan and D. Zhang, “Blood glucose prediction by breath analysis
system with feature selection and model fusion,” in 36th Annual Inter-
national Conference of the IEEE Engineering in Medicine and Biology
Society, Aug. 2014, pp. 6406–6409.
[12] H. Abdi and L. J. Williams, “Principal component analysis,” Wiley
Interdisciplinary Reviews: Computational Statistics, vol. 2, no. 4, pp.
433–459, 2010.
[13] K. Polat, S. Gne, and A. Arslan, “A cascade learning system for
classification of diabetes disease: Generalized discriminant analysis and
least square support vector machine,” Expert Systems with Applications,
vol. 34, no. 1, pp. 482 – 487, 2008.
[14] C. Pe´rez-Gandı´a, A. Facchinetti, G. Sparacino, C. Cobelli, E. Go´mez,
M. Rigla, A. de Leiva, and M. Hernando, “Artificial neural network
algorithm for online glucose prediction from continuous glucose moni-
toring,” Diabetes technology & therapeutics, vol. 12, no. 1, pp. 81–88,
2010.
[15] C. Zecchin, A. Facchinetti, G. Sparacino, G. D. Nicolao, and C. Cobelli,
“Neural network incorporating meal information improves accuracy of
short-time prediction of glucose concentration,” IEEE Transactions on
Biomedical Engineering, vol. 59, no. 6, pp. 1550–1560, Jun. 2012.
[16] K. Plis, R. Bunescu, C. Marling, J. Shubrook, and F. Schwartz, “A ma-
chine learning approach to predicting blood glucose levels for diabetes
management,” in Modern Artificial Intelligence for Health Analytics
Papers from the AAAI-14.
[17] H. Mhaskar, S. Pereverzyev, and M. van der Walt, “A
deep learning approach to diabetic blood glucose prediction,”
https://arxiv.org/abs/1707.05828, 2017.
[18] C. Marling and R. Bunescu, “The OhioT1DM dataset for blood glucose
level prediction,” in The 3rd International Workshop on Knowledge
Discovery in Healthcare Data, Stockholm, Sweden, July 2018.
[19] Y. Jia, E. Shelhamer, J. Donahue, S. Karayev, J. Long, R. Girshick,
S. Guadarrama, and T. Darrell, “Caffe: Convolutional architecture for
fast feature embedding,” in Proceedings of the 22Nd ACM International
Conference on Multimedia, ser. MM ’14, 2014, pp. 675–678.
[20] G. Litjens, C. I. Snchez, N. Timofeeva, M. Hermsen, I. Nagtegaal,
I. Kovacs, C. H. van de Kaa, P. Bult, B. van Ginneken, and J. van der
Laak, “Deep learning as a tool for increased accuracy and efficiency of
histopathological diagnosis,” Scientific Reports, vol. 6, p. 26286, May
2016.
[21] R. Miotto, F. Wang, S. Wang, X. Jiang, and J. T. Dudley, “Deep
learning for healthcare: review, opportunities and challenges,” Briefings
in Bioinformatics, vol. 19, no. 6, pp. 1236–1246, 05 2017. [Online].
Available: https://dx.doi.org/10.1093/bib/bbx044
[22] T. Zhu, K. Li, P. Herrero, J. Chen, and P. Georgiou, “A deep learn-
ing algorithm for personalized blood glucose prediction,” in The 3rd
International Workshop on Knowledge Discovery in Healthcare Data,
IJCAI-ECAI 2018.
[23] Y. Bengio, “Deep learning of representations: Looking forward,” in
Statistical Language and Speech Processing. Berlin, Heidelberg:
Springer Berlin Heidelberg, 2013, pp. 1–37.
[24] J. Schmidhuber, “Deep learning in neural networks: An overview,”
Neural Networks, vol. 61, pp. 85 – 117, 2015.
[25] K. Li, A. Javer, E. Keaveny, and A. Brown, “Recurrent neural networks
with interpretable cells predict and classify worm behaviour,” in Work-
shop on Worm’s Neural Information Processing (WNIP) in NIPS, CA,
USA, 2017.
[26] Q. Zhang, Y. N. Wu, and S.-C. Zhu, “Interpretable convolutional neural
networks,” in The IEEE Conference on Computer Vision and Pattern
Recognition (CVPR), Jun. 2018, pp. 8827–8836.
[27] I. Goodfellow, Y. Bengio, and A. Courville, Deep Learning. The MIT
Press, 2016.
[28] M. Abadi, A. Agarwal, P. Barham, E. Brevdo, Z. Chen, C. Citro, G. S.
Corrado, A. Davis, J. Dean, M. Devin, S. Ghemawat, I. Goodfellow,
A. Harp, G. Irving, M. Isard, Y. Jia, R. Jozefowicz, L. Kaiser, M. Kudlur,
J. Levenberg, D. Mane´, R. Monga, S. Moore, D. Murray, C. Olah,
M. Schuster, J. Shlens, B. Steiner, I. Sutskever, K. Talwar, P. Tucker,
V. Vanhoucke, V. Vasudevan, F. Vie´gas, O. Vinyals, P. Warden, M. Wat-
tenberg, M. Wicke, Y. Yu, and X. Zheng, “TensorFlow: Large-scale
machine learning on heterogeneous systems,” 2015, software available
from tensorflow.org.
[29] C. Zhao, E. Dassau, L. Jovanovic, H. C. Zisser, I. Francis J. Doyle,
and D. E. Seborg, “Predicting subcutaneous glucose concentration using
a latent-variable-based statistical method for type 1 diabetes mellitus,”
Journal of Diabetes Science and Technology, vol. 6, no. 3, pp. 617–633,
2012.
[30] D. A. Finan, F. J. Doyle III, C. C. Palerm, W. C. Bevier, H. C. Zisser,
L. Jovanovicˇ, and D. E. Seborg, “Experimental evaluation of a recursive
model identification technique for type 1 diabetes,” Journal of diabetes
science and technology, vol. 3, no. 5, pp. 1192–1202, 2009.
[31] C. D. Man, F. Micheletto, D. Lv, M. Breton, B. Kovatchev, and
C. Cobelli, “The uva/padova type 1 diabetes simulator,” Jounral of
Diabetes Sci Technol., vol. 8, no. 1, pp. 26–34, Jan. 2014.
[32] P. Herrero, J. Bondia, O. Adewuyi, P. Pesl, M. El-Sharkawy, M. Reddy,
C. Toumazou, N. Oliver, and P. Georgiou, “Enhancing automatic closed-
loop glucose control in type 1 diabetes with an adaptive meal bolus
calculator–in silico evaluation under intra-day variability,” Computer
Methods and Programs in Biomedicine, vol. 146, pp. 125–131, 2017.
[33] M. Reddy, P. Pesl, M. Xenou, C. Toumazou, D. Johnston, P. Georgiou,
P. Herrero, and N. Oliver, “Clinical safety and feasibility of the advanced
bolus calculator for type 1 diabetes based on case-based reasoning: A
6-week nonrandomized single-arm pilot study,” Diabetes Technology &
Therapeutics, vol. 18, no. 8, pp. 487–493, 2016.
[34] G. Sparacino, F. Zanderigo, S. Corazza, A. Maran, A. Facchinetti, and
C. Cobelli, “Glucose concentration can be predicted ahead in time from
continuous glucose monitoring sensor time-series,” IEEE Transactions
on Biomedical Engineering, vol. 54, no. 5, pp. 931–937, May 2007.
[35] S. G. Mougiakakou, A. Prountzou, D. Iliopoulou, K. S. Nikita,
A. Vazeou, and C. S. Bartsocas, “Neural network based glucose -
insulin metabolism models for children with type 1 diabetes,” in 2006
International Conference of the IEEE Engineering in Medicine and
Biology Society, Aug. 2006, pp. 3545–3548.
[36] R. Atanassov, P. Bose, M. Couture, A. Maheshwari, P. Morin, M. Paque-
tte, M. Smid, and S. Wuhrer, “Algorithms for optimal outlier removal,”
Journal of Discrete Algorithms, vol. 7, no. 2, pp. 239 – 248, 2009,
selected papers from the 2nd Algorithms and Complexity in Durham
Workshop ACiD 2006.
[37] H. Shum, K. Ikeuchi, and R. Reddy, Principal Component Analysis
with Missing Data and Its Application to Polyhedral Object Modeling.
Boston, MA: Springer US, 2001, pp. 3–39.
[38] D. Li, J. Deogun, W. Spaulding, and B. Shuart, “Towards missing data
imputation: A study of fuzzy k-means clustering method,” in Rough Sets
and Current Trends in Computing. Berlin, Heidelberg: Springer Berlin
Heidelberg, 2004, pp. 573–579.
[39] L. Lekha and S. M, “Real-time non-invasive detection and classification
of diabetes using modified convolution neural network,” IEEE Journal
of Biomedical and Health Informatics, vol. 22, no. 5, pp. 1630–1636,
2018.
[40] S. Hochreiter and J. Schmidhuber, “Long Short-Term Memory,” Neural
Computation, vol. 9, no. 8, pp. 1735–1780, 1997.
[41] A. Graves, A. R. Mohamed, and G. Hinton, “Speech recognition with
deep recurrent neural networks,” in IEEE Int. Conf. on Acou., Spe. and
Sig. Proc., 2013, p. 6645.
[42] N. Srivastava, G. E. Hinton, A. Krizhevsky, I. Sutskever, and
R. Salakhutdinov, “Dropout: a simple way to prevent neural networks
from overfitting.” Journal of Machine Learning Research, vol. 15, no. 1,
pp. 1929–1958, 2014.
[43] S. Ruder, “An overview of gradient descent optimization algorithms,”
2016. [Online]. Available: preprintarXiv:1609.04747
[44] International Hypoglycaemia Study Group, “Glucose Concentrations of
Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical
Trials: A Joint Position Statement of the American Diabetes Association
and the European Association for the Study of Diabetes: Table 1,”
Diabetes Care, vol. 40, no. 1, pp. 155–157, Jan. 2017.
